Chemoinformaics analysis of 2,6-Dimethylpyridine
| Molecular Weight | 107.156 | nRot | 0 |
| Heavy Atom Molecular Weight | 98.084 | nRig | 6 |
| Exact Molecular Weight | 107.074 | nRing | 1 |
| Solubility: LogS | 0.027 | nHRing | 1 |
| Solubility: LogP | 1.344 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 17 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 8 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 9 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 7 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 6 |
| nHA | 1 | APOL | 18.7911 |
| nHD | 0 | BPOL | 10.1689 |
| QED | 0.491 |
| Synth | 1.665 |
| Natural Product Likeliness | -1.139 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.005 |
| HIA | 0.003 |
| CACO-2 | -4.529 |
| MDCK | 0.0000365 |
| BBB | 0.94 |
| PPB | 0.566761 |
| VDSS | 0.818 |
| FU | 0.413837 |
| CYP1A2-inh | 0.674 |
| CYP1A2-sub | 0.861 |
| CYP2c19-inh | 0.054 |
| CYP2c19-sub | 0.631 |
| CYP2c9-inh | 0.009 |
| CYP2c9-sub | 0.125 |
| CYP2d6-inh | 0.254 |
| CYP2d6-sub | 0.785 |
| CYP3a4-inh | 0.02 |
| CYP3a4-sub | 0.382 |
| CL | 6.742 |
| T12 | 0.447 |
| hERG | 0.026 |
| Ames | 0.078 |
| ROA | 0.91 |
| SkinSen | 0.586 |
| Carcinogencity | 0.679 |
| EI | 0.992 |
| Respiratory | 0.958 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.911779 |